Shanghai Fushang Huichuang Pharmaceutical Research Co Ltd

Primary study objective: To evaluate and compare the pharmacokinetic characteristics of FCN-437c in subjects with mild and moderate liver impairment and healthy subjects, and to provide a basis for clinical medication in patients with liver impairment Secondary study objective: To evaluate the safety of FCN-437c in subjects with mild and moderate liver impairment and healthy subjects

[Main study objectives] Evaluate the effect of FCN-437c blood concentration on QT interval by C-QTc effect model. [Secondary study objectives] 1. Evaluate the safety of a single oral administration of 300mg or 400mg FCN-437c capsules to healthy subjects; 2. Evaluate the pharmacokinetic characteristics of FCN-437c after a single oral administration of 300mg or 400mg FCN-437c capsules to healthy subjects.

[Main study objectives] 1 To quantitatively analyze the total radioactivity in excreta after oral administration of [14C]FCN-437c to healthy male subjects, and obtain the cumulative excretion rate and main excretion pathway of human radioactivity; 2 To investigate the distribution of [14C]FCN-437c in whole blood and plasma and the pharmacokinetics of total radioactivity in plasma after a single oral administration of [14C]FCN-437c to healthy male subjects; 3 To identify the main metabolites in plasma, urine and feces after oral administration of [14C]FCN-437c to healthy male subjects, and determine the main biotransformation pathways and main metabolites; 4 To quantitatively analyze the concentration of FCN-437c and its main metabolites in plasma using a validated LC-MS/MS method, and obtain the pharmacokinetic parameters of FCN-437c and its main metabolites in plasma. [Secondary study objectives] To observe the safety of healthy male subjects after a single administration of [14C]FCN-437c.